Eaton plans to begin development of transdermal patch delivery system for Tropine 3

Sep 11 2012

Eaton Scientific Systems, Ltd. ("Eaton" or the "Company") a wholly-owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to announce that the Company plans to begin development of a transdermal patch delivery system for Tropine 3, a patent pending novel indication of homatropine for non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women.  The Company believes that this will be the world's first ever available prescription non-hormonal transdermal treatment for hot flash symptoms.

"Tropine 3 is an ideal type of medication to utilize the convenience and dose control accuracy of a transdermal medicated patch delivery system," stated Michael Borkowski, CEO of Eaton Scientific.  "Based upon the popular use of Estrogen patches in hormone replacement therapy, it's readily apparent that a high percentage of women could have the same preference when choosing a safe non-hormonal transdermal patch to safely reduce their hot flashes symptoms.  We feel this is an opportunity to develop another unique, marketable, and potential patentable feature exclusive to Tropine 3 and Eaton Scientific."

The Company intends to contract with an industry leading drug delivery system expert to assist in the development of the transdermal Tropine 3 patch. Initial testing of various monolithic device transdermal patch technologies and configurations is expected to begin in conjunction with the Company's planned FDA compliant Tropine 3 clinical studies currently being organized to start in the next few weeks.

The transdermal patch was first approved by the U.S. FDA in 1979 as a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream.  The main advantage of a transdermal drug delivery route is that the patch provides a long-term controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.  Only medications whose molecules are small enough to penetrate the skin can be delivered by transdermal patch.  Tropine 3 (homatropine in suspension) molecules are thought to be ideal for transdermal patch delivery.